Presentation1_IL-21 Optimizes the CAR-T Cell Preparation Through Improving Lentivirus Mediated Transfection Efficiency of T Cells and Enhancing CAR-T Cell Cytotoxic Activities.PPTX
Adoptive immunotherapy using CAR-T cells is a promising curative treatment strategy for hematological malignancies. Current manufacture of clinical-grade CAR-T cells based on lentiviral/retrovirus transfection of T cells followed by anti-CD3/CD28 activation supplemented with IL-2 has been associated with low transfection efficiency and usually based on the use of terminally differentiated effector T cells. Thus, improving the quality and the quantity of CAR-T cells are essential for optimizing the CAR-T cell preparation. In our study, we focus on the role of IL-21 in the γc cytokine conditions for CAR-T cell preparation. We found for the first time that the addition of IL-21 in the CAR-T preparation improved T cell transfection efficiency through the reduction of IFN-γ expression 24–48 h after T cell activation. We also confirmed that IL-21 enhanced the enrichment and expansion of less differentiated CAR-T cells. Finally, we validated that IL-21 improved the CAR-T cell cytotoxicity, which was related to increased secretion of effector cytokines. Together, these findings can be used to optimize the CAR-T cell preparation.
History
References
- https://doi.org//10.1038/nbt.4086
- https://doi.org//10.1038/ncomms8562
- https://doi.org//10.1158/2326-6066.CIR-18-0466
- https://doi.org//10.1158/2326-6066.CIR-19-0293
- https://doi.org//10.1016/j.ymthe.2017.10.002
- https://doi.org//10.1038/365666a0
- https://doi.org//10.1073/pnas.89.10.4285
- https://doi.org//10.1182/blood-2006-10-05497310.1016/j.immuni.2011.09.017
- https://doi.org//10.3389/fimmu.2019.00263
- https://doi.org//10.1038/s41467-018-02912-x
- https://doi.org//10.1101/cshperspect.a028464
- https://doi.org//10.1016/j.smim.2019.10130710.3389/fimmu.2020.01941
- https://doi.org//10.1016/0959-8049%2896%2900015-9
- https://doi.org//10.1126/science.aaa6204
- https://doi.org//10.1038/nature12626
- https://doi.org//10.1038/nm.4478
- https://doi.org//10.1515/bmc-2018-0007
- https://doi.org//10.1016/j.immuni.2009.11.010
- https://doi.org//10.1007/978-1-4939-3753-0_7
- https://doi.org//10.1128/JVI.00485-12
- https://doi.org//10.1084/jem.20192203
- https://doi.org//10.1038/nri1688
- https://doi.org//10.1182/blood-2007-05-089375
- https://doi.org//10.18632/oncotarget.24442
- https://doi.org//10.1182/blood-2009-09-241398
- https://doi.org//10.1007/s40265-019-01071-7
- https://doi.org//10.1056/NEJMoa1709866
- https://doi.org//10.1126/scitranslmed.aaa0984
- https://doi.org//10.1016/j.immuni.2004.07.016
- https://doi.org//10.1056/NEJMoa1709919
- https://doi.org//10.1182/blood-2015-11-683847
- https://doi.org//10.1089/hum.2012.229
- https://doi.org//10.1038/nri1052
- https://doi.org//10.7150/thno.44715
- https://doi.org//10.1016/j.smim.2019.101307
- https://doi.org//10.1038/srep20070
- https://doi.org//10.4049/jimmunol.1201730
- https://doi.org//10.1182/blood-2006-10-054973
- https://doi.org//10.1084/jem.20041057
- https://doi.org//10.4049/jimmunol.0900447
CC BY 4.0